‌

US Patent 10525145 ExPEC glycoconjugate vaccine formulations

Patent 10525145 was granted and assigned to Janssen Pharmaceuticals on January, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Janssen Pharmaceuticals

0

Current Assignee

Janssen Pharmaceuticals

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Wouter Frank Tonnis0

Janik Adriaansen0

Olga Labovitiadi0

Francesco Doro0

Date of Patent

January 7, 2020

0

Patent Application Number

161916590

Date Filed

November 15, 2018

0

Patent Citations Received

US Patent 11491220 Methods of producing bioconjugates of

US Patent 11529405 MDR

US Patent 11446370 Bioconjugates of

US Patent 11931405 Bioconjugates of

0

US Patent 12076385 Methods and compositions for immune protection against extra-intestinal pathogenic

0

Patent Primary Examiner

0

Patent abstract

Compositions and methods for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) are described. In particular, multivalent vaccines containing E. coli antigen polysaccharide covalently bound to a exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein that can withstand multiple environmental stresses are described.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10525145 ExPEC glycoconjugate vaccine formulations

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.